<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763893</url>
  </required_header>
  <id_info>
    <org_study_id>P060210</org_study_id>
    <secondary_id>2006-006112-30</secondary_id>
    <nct_id>NCT00763893</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome</brief_title>
  <acronym>MARFANSARTAN</acronym>
  <official_title>Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - H么pitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if losartan limits aortic dilatation in patients
      with Marfan syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim : evaluate the efficacy of losartan for limiting aortic dilatation in patients with
      marfan syndrome receiving standard therapy

      Inclusion criteria :

      10 years or older Marfan syndrome according to international criteria Signed informed consent

      Non inclusion :

      Previous surgery of the ascending aorta, or surgery planned Non echogenicity
      Contre-indication lactose Pregnancy on going or planned within 3 years Breast feeding
      Participation in another clinical study Non member of the social security or CMU

      Number of subjects : the number of subjects (150 per group) is derived from the study from
      Shores et al (1994) demonstrating the benefit of beta-blockade in Marfan patient and uses a
      decrease by half of the aortic dilatation with losartan

      Follow-up is 3 years, after inclusion period of 2 years. A total of 5 years is expected

      Methods : randomised double blind vs placebo study. All French centres de competence for
      marfan syndrome and the centre de reference are participating in the study.

      End points : main endpoint is evolution of normalised aortic diameter. Secondary endpoints
      include clinical events (cardiac surgery or aortic dissection, hospitalisation in cardiology
      department, death), tolerance of the drug, and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A similar publication has been released, suggesting a beneficial effect of sartans, and only 15
    patients remained to be seen for their visit at 36 months.
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>normalised aortic diameter at the level of the sinus of valsalva</measure>
    <time_frame>every six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac surgery, hospitalisation in cardiology ward, death</measure>
    <time_frame>during the follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Marfan Syndrome</condition>
  <arm_group>
    <arm_group_label>A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.</description>
    <arm_group_label>A: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>50 mg/day if &lt; weight 50 kg 100 mg/day if weight &gt; 50 kg</description>
    <arm_group_label>B: Losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  10 years or older

          -  Marfan syndrome according to international criteria Signed informed consent

        Exclusion Criteria:

          -  Previous surgery of the ascending aorta, or surgery planned

          -  Non echogenicity

          -  Contre-indication lactose

          -  Pregnancy on going or planned within 3 years

          -  Breast feeding

          -  Participation in another clinical study

          -  Non member of the social security or CMU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume JONDEAU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - H么pitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H么pital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Detaint D, Aegerter P, Tubach F, Hoffman I, Plauchu H, Dulac Y, Faivre LO, Delrue MA, Collignon P, Odent S, Tchitchinadze M, Bouffard C, Arnoult F, Gautier M, Boileau C, Jondeau G. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis. 2010 May;103(5):317-25. doi: 10.1016/j.acvd.2010.04.008. Epub 2010 Jul 1.</citation>
    <PMID>20619242</PMID>
  </results_reference>
  <results_reference>
    <citation>Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D, Tubach F, Dupuis-Girod S, Plauchu H, Barthelet M, Sassolas F, Pangaud N, Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE, Faivre L, Odent S, Basquin A, Habib G, Collignon P, Boileau C, Jondeau G. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015 Aug 21;36(32):2160-6. doi: 10.1093/eurheartj/ehv151. Epub 2015 May 2.</citation>
    <PMID>25935877</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Marfan syndrome</keyword>
  <keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
  <keyword>Aortic Aneurysm, Thoracic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Marfan Syndrome</mesh_term>
    <mesh_term>Arachnodactyly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

